Abstract

This is the largest global industry gathering for the orphan drug industry and rare disease community where pharma, biotech, patient groups, academia, regulators, payers and investors gather to talk about strategies to expedite orphan drug development. We grew the event to 600 participants in 2015 with over 25 countries represented. cademic medical centers, HCPs, clinicians and point of care diagnostics will be a new focus in 2016. Specific orphan products and their Marketing Managers will also be a stronger focus along with gene therapy as the future rare disease cure. Meet CEOs, VPs and Directors of the following business units from pharma and biotech: R&D, Business Development, Regulatory Access, Market Access, Commercial, Marketing and Brand/Product Managers.You will also meet Scientists, Investigators and Engineers as well as relevant Heads from university departments studying rare disease and developing a cure.